Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.69 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.63 |
| ▸ | OSBP | P22059 | 4/20 | 0.61 |
| ▸ | RORC | P51449 | 3/20 | 0.61 |
| ▸ | USP2 | O75604 | 2/20 | 0.61 |
| ▸ | OSBP2 | Q969R2 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.61 |
| ▸ | GBA1 | P04062 | 2/20 | 0.60 |
| ▸ | UGCG | Q16739 | 2/20 | 0.60 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.60 |
| ▸ | NPC1L1 | Q9UHC9 | 6/20 | 0.58 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | CRYAB | P02511 | 1/20 | 0.50 |
| ▸ | HMGCR | P04035 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGAV | P06756 | 1/20 | 0.50 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22644915 | 1.00 | POLA1 (0.69) | POLA1CYP46A1OSBPRORCUSP2 | |
| SCHEMBL24081051 | 1.00 | POLA1 (0.69) | POLA1CYP46A1OSBPRORCUSP2 | |
| SCHEMBL17779818 | 1.00 | POLA1 (0.69) | POLA1CYP46A1OSBPRORCUSP2 | |
| SCHEMBL16306911 | 1.00 | POLA1 (0.69) | POLA1CYP46A1OSBPRORCUSP2 | |
| SCHEMBL22292578 | 1.00 | POLA1 (0.69) | POLA1CYP46A1OSBPRORCUSP2 | |
| SCHEMBL17779715 | 0.90 | POLA1 (0.63) | POLA1CYP46A1OSBPRORCUSP2 | |
| SCHEMBL22644913 | 0.90 | POLA1 (0.63) | POLA1CYP46A1OSBPRORCUSP2 | |
| SCHEMBL17775697 | 0.89 | POLA1 (0.79) | POLA1CYP46A1OSBPRORCUSP2 | |
| SCHEMBL17775711 | 0.89 | POLA1 (0.79) | POLA1CYP46A1OSBPRORCUSP2 | |
| SCHEMBL17779714 | 0.89 | POLA1 (0.64) | POLA1CYP46A1OSBPRORCUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3007709-B1 | LIPID-BASED PLATINUM COMPOUNDS AND NANOPARTICLES | AKAMARA THERAPEUTICS INC (US) | 2021-12-08 | — | — | EP | disclosed |
| US-10730899-B2 | Lipid-based platinum compounds and nanoparticles | Akamara Therapeutics, Inc. (US) | 2020-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730899-B2 | Lipid-based platinum compounds and nanoparticles | SGMS1, SGMS2, PHOSPHO1 | POLA1 2085/4885CYP46A1 1184/4885OSBP 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.